Ateb adds two heavy hitters to its roster
RALEIGH, N.C. — Ateb recently named Rebecca Chater as its executive healthcare strategist and added Bjorn Thommesen to the team.
Chater will provide clinical leadership of Ateb’s patient care support solutions and thought leadership to influence broad integration of pharmacy and pharmacist services among healthcare stakeholders to improve patient care coordination and health outcomes.
Chater brings to Ateb more than twenty years of professional leadership and innovation and was a pioneer in the historical Asheville Project, which continues to serve as a model for delivering health solutions and patient-centric care through community pharmacy to improve health outcomes and lower overall costs.
Chater is a past president and 10-year elected-member of the North Carolina Board of Pharmacy, and has served as Visiting Clinical Assistant Professor in the department of pharmacotherapy at the University of North Carolina Eshelman School of Pharmacy. She is a recipient of the North Carolina Association of Pharmacists Innovative Practice Award and the UNC Eshelman School of Pharmacy Distinguished Service Award. She earned both her master’s degree in public health and her bachelor of science in pharmacy at the University of North Carolina at Chapel Hill.
Thommesen will focus on providing solutions for pharmacy to better patient health and increase adherence. He comes to Ateb from RxAlly to provide his expertise in consultative selling, business development and health plan and payer solutions.
Thommesen has more than a decade of experience in consultative selling to Medicare, Medicaid and commercial health plans and employers. His emphasis has been on solutions that improve healthcare delivery and patient health outcomes, while reducing costs for payers and increasing quality and member satisfaction scores, including HEDIS, STAR and CAHPS.
Before joining Ateb, Thommesen worked for such industry leaders as HealthPartners, UnitedHealthCare, Amerigroup Corporation and Express Scripts. Thommesen has a proven track record of helping lower healthcare costs by facilitating relationships between advanced clinical programs and community pharmacists and patients. In support of the same goals, both Ateb and Thommesen are determined to continue to assist pharmacies to be recognized and remunerated for providing patient-centric care and clinical solutions to improve patient health outcomes.
No comments found
Teva approved for new dose of Copaxone
JERUSALEM — Teva Pharmaceutical Industries on Tuesday announced that the Food and Drug Administration approved its supplemental new drug application for three-times-a-week Copaxone in 40mg/mL. Daily Copaxone in 20mg/mL dosage will continue to be available.
Copaxone is administered to patients with relapsing forms of multiple sclerosis. The new formulation will allow for a less frequent dosing regimen.
“The availability of three-times-a-week Copaxone 40 mg/mL is a significant advancement for patients, as they now have the option of effective and safe treatment with Copaxone, while reducing the number of injections by 60%,” Omar Khan, M.D., professor of neurology and chair of the department of neurology at Wayne State University School of Medicine, said. “Patients in the United States can now benefit from an improved dosing regimen without compromising the known benefits of Copaxone.”
Three-times-a-week Copaxone 40mg/mL is available for shipping immediately.
No comments found
Report: Specialty pharmacy to account for half of all prescription revenue by 2018
PHILADELPHIA — Almost two-thirds of specialty pharmacy revenues are attributed to 1-of-3 companies, and the specialty pharmacy market is poised to explode, according to a Drug Channels Institute report released Tuesday.
"Three companies — Express Scripts, CVS Caremark and Walgreens — account for 63% of revenues from pharmacy-dispensed specialty medications that treat such illnesses as cancer, multiple sclerosis and rheumatoid arthritis,” stated Drug Channels Institute CEO Adam J. Fein, the study’s author and a widely regarded expert on pharmacy economics and the pharmaceutical supply chain. “By 2018, 50% of industry revenues will come from specialty drugs,” Fein added. “Drug stores, hospitals, physician, wholesalers and health plans are all battling for position in this fast-growing market.”
The report, called "2013-14 Economic Report on Retail, Mail and Specialty Pharmacies," is a 185-page analysis of the $287 billion U.S. pharmacy industry with 98 proprietary charts, exhibits and data tables. What’s more, the institute analyzes how healthcare reform will affect pharmacies. It explores such factors as the healthcare coverage expansion, forthcoming Medicaid pharmacy reimbursement changes, the boom in narrow pharmacy networks for Medicare drug plans and unprecedented growth in the 340B drug discount program.
Every competition will be destroyed by these monopolies that exist by complicit government inaction. - Adam Gottbetter
Due to the risks and expense involved with Specialty Pharmacy Medications, it's critical that retail community pharmacist be involved with delivering the necessary pharmaceutical care and medication management services required to ensure optimal use. This is not the type of care to be delivered by off-site professionals who do not have a relationship with the patient. Otherwise physicians would adopt the same remote care treatment model. Plus patients should have a right to choose their pharmacist. The next important step for pharmacists to take is to communicate patient risks and concerns with this care model to CMS. Otherwise we could end up with additional health care risks and costs not unlike some of those acknowledged recently in the Policy and Technical Changes to the Medicare Advantage and the Medicare Prescription Drug Benefit Programs for Contract Year 2015 (CMS-4159-P)